🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  2. LEN+SIN+DEB-TACE+HAIC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma Non-resectable

    phase 2 other active

    1 trial

  3. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

  4. LICSBR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. LM-108 antibody and sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  6. LN-145, ALDESLEUKIN, Lifileucel, Fludarabine 50mg Powder For Solution For Injection Or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, NIVOLUMAB, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Accord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui, IPILIMUMAB, Cyclophosphamide Injection 1 g.

    Iovance Biotherapeutics B.V.

    Neoplasm

    phase 2 small molecule active

    1 trial

  7. LOMUSTINE , Odomzo 200 mg hard capsules, VINCRISTINE, CISPLATIN

    Ningbo Cancer Hospital

    Newly Diagnosed Medulloblastoma

    phase 2 small molecule active

    1 trial

  8. LOU064, -, -, Placebo to LOU064 Film-coated tablet

    Novartis Pharmaceuticals

    Chronic Inducible urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  9. LP-98 20 mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 2 small molecule active

    1 trial

  10. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  11. Lactulose

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Constipation

    phase 2 small molecule completed

    1 trial

  12. Laminectomy

    Biotech Pharmaceutical Co.,

    Acute Spinal Cord Injury

    phase 2 other active

    1 trial

  13. Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. Lanthanum Polystyrene Sulphonate Powder

    The First People's Hospital of Lianyungang

    Hyperphosphatemia

    phase 2 small molecule active

    1 trial

  15. Late immunity following single immunization with GA2 sporozoites (GACHA)

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  16. Lenalidomide

    The First People's Hospital of Lianyungang

    PTCL, NOS

    phase 2 small molecule active

    1 trial

  17. Lenalidomide [Leavdo®]

    Hospital Authority, Hong Kong

    Antibiotics-unresponsive MALT Lymphoma

    phase 2 small molecule active

    1 trial

  18. Lenalidomide and Gemcitabine (Dose level 11)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T-cell Lymphomas (PTCL)

    phase 2 small molecule terminated

    1 trial

  19. Lenalidomide combined with G-CHOP (LO CHOP)

    The First People's Hospital of Lianyungang

    DLBCL - Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  20. Lenvatinib

    The First People's Hospital of Lianyungang

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  21. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830, ETOPOSIDE, Lenvatinib, CISPLATIN, boserolimab, CARBOPLATIN

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  22. Lenvima 4 mg Oral Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  23. Letrozole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasms

    phase 2 small molecule active

    1 trial

  24. Levact 2,5 mg/ml, polvo para concentrado para solución para perfusión., Beneflur10 mg comprimidos recubiertos con película, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión, HSP-CAR19M

    The George Institute

    Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources